ANTIDEPRESSANTS, OTHER PRIOR AUTHORIZATION FORM

(form effective 7/15/2024)

Keystone First | PERFORMRx℠ Next Generation Pharmacy Benefits

Fax to PerformRx℠ at **1-866-497-1387**, or to speak to a representative call **1-800-588-6767**.

PRIOR AUTHORIZATION REQUEST INFORMATION

☐ New request ☐ Renewal request	Total # of pages:	
Name of office contact:	Contact's phone number:	LTC facility contact/phone:

BENEFICIARY INFORMATION

Beneficiary name:	Beneficiary ID#:	DOB:
Street address:		
Apt #: City/state/zip:	Phone:	

PRESCRIBER INFORMATION

Prescriber name:		
Specialty:	NPI:	State license #:
Street address:		
Suite #: City/state/zip:		
Phone:	Fax:	

CLINICAL INFORMATION

Drug requested:		
Strength:	Dosage form:	
Dose and directions:	Quantity:	Refills:
Diagnosis *(submit documentation)*:		Dx code *(required)*:
Is the beneficiary currently being treated with the requested medication?		☐ Yes – *date of last dose:* *Submit documentation.* ☐ No

INITIAL REQUESTS

Complete all sections that apply to the beneficiary and this request.
Check all that apply and *submit documentation* for each item.

1. For ZULRESSO (brexanolone) and ZURZUVAE (zuranolone):

☐ Is being treated for postpartum depression (PPD) AND:
- ☐ Has depression with onset in the 3rd trimester through 4 weeks postpartum.
- ☐ Has moderate to severe PPD based on a validated depression rating scale (e.g., PHQ-9/EPDS, HAMD-17).
- ☐ Is less than or equal to 12 months postpartum.
- ☐ Is not actively psychotic, manic, or hypomanic.
- ☐ Is not currently pregnant.

2. For ALL OTHER NON-PREFERRED Antidepressants, Other (except Zulresso and Zurzuvae):

☐ Tried and failed or has a contraindication or an intolerance to the preferred Antidepressants, Other that are FDA-approved or medically accepted for the treatment of the beneficiary's diagnosis at maximally tolerated doses for at least 6 weeks. *(Refer to https://papdl.com/preferred-drug-list for a list of preferred Antidepressants, Other.)*

List preferred medications tried:_____

☐ Tried and failed or has a contraindication or an intolerance to the Antidepressants, SSRIs that are FDA-approved or medically accepted for the treatment of the beneficiary's diagnosis at maximally tolerated doses for at least 6 weeks.
- ☐ citalopram (e.g., Celexa)
- ☐ escitalopram (e.g., Lexapro)
- ☐ fluoxetine (e.g., Prozac, Sarafem)
- ☐ fluvoxamine (e.g., Luvox)
- ☐ paroxetine (e.g., Paxil, Pexeva)
- ☐ sertraline (e.g., Zoloft)

☐ Tried and failed or has a contraindication or an intolerance to augmentation therapy (e.g., lithium, antipsychotic, stimulant) in combination with an antidepressant that is FDA-approved or medically accepted for the treatment of the beneficiary's diagnosis at maximally tolerated doses for at least 6 weeks.

List preferred medications tried:_____

3. For SPRAVATO (esketamine):

☐ Is prescribed Spravato by or in consultation with a psychiatrist.

☐ Will use Spravato in conjunction with a therapeutic dose of an oral antidepressant.

☐ Does not have severe hepatic impairment (Child-Pugh class C).

RENEWAL REQUESTS

1. For SPRAVATO (esketamine):

☐ Is prescribed Spravato by or in consultation with a psychiatrist.

☐ Will use Spravato in conjunction with a therapeutic dose of an oral antidepressant.

☐ Does not have severe hepatic impairment (Child-Pugh class C).

☐ Has documentation of improvement in disease severity since starting treatment.

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION

Prescriber signature:	Date:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or taking of any telecopy is strictly prohibited.